166 related articles for article (PubMed ID: 18712279)
1. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
[TBL] [Abstract][Full Text] [Related]
2. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
[TBL] [Abstract][Full Text] [Related]
3. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
5. Successful treatment of a brain-metastasized renal cell carcinoma.
Walid MS; Johnston KW
Ger Med Sci; 2009 Oct; 7():Doc28. PubMed ID: 19911072
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
8. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
10. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Tomita Y
Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
[No Abstract] [Full Text] [Related]
12. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Hill KL; Lipson AC; Sheehan JM
J Neurosurg; 2009 Sep; 111(3):497-503. PubMed ID: 19199506
[TBL] [Abstract][Full Text] [Related]
13. A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
Benincasa E; Conti A; Bossone G; Gallà DA; Gianciotta A; Zuccaro SM; Madaio R
Tumori; 2009; 95(3):403. PubMed ID: 19688987
[No Abstract] [Full Text] [Related]
14. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
15. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
17. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
18. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
19. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Wu Y; Zhao Y
Int J Urol; 2011 Jun; 18(6):430-1. PubMed ID: 21599760
[No Abstract] [Full Text] [Related]
20. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
[Next] [New Search]
